Combating Sleep Disorders in Parkinson's Disease

Video

Aleksandar Videnovic, MD, associate professor at the Massachusetts General Hospital, discusses new patient monitoring opportunities and other methods of treatment for one of Parkinson's disease patients' most common symptoms.

Sleep disorder is prevalent in almost every Parkinson’s disease (PD) patient, worsening the efficacy of their own treatment and quality of life.

These disorders are not just about night-time sleep, Aleksandar Videnovic, MD, said. It’s about day-time function, and it includes a “rich phenotype” of disorders.

“Therefore, good treatment paradigm really needs to start with the discussion about symptoms leading to diagnosis,” Videnovic said.

Videnovic, associate professor at Massachusetts General Hospital, spoke about the debilitating effects of sleep disorder in PD patients the 21st International Congress of Parkinson’s Disease and Movement Disorders in Vancouber, BC. But treatment optimization and advancements in patient monitoring are aiding those it affects.

“We will certainly see more emphasis on important monitoring with these devices that are being specifically designed for the Parkinson’s disease population,” Videnovic said. “There are a lot of these sleep monitoring apps and paradigms that already in the market for available use for general sleep assessment.”

Videnovic sees these programs and apps coming into the mainstream of PD treatment, helping clinicians see the sleep dynamics of patients while not costing them the comfort of home care.

These advancements, as long as advocacy for healthy exercise and diet to supplement treatment efficacy, will aid those inflicted with one of PD’s most common and most difficult symptoms.

Recent Videos
Arshad Khanani, MD: Four-Year Outcomes of Faricimab for DME in RHONE-X | Image Credit: Sierra Eye Associates
Dilraj Grewal, MD: Development of MNV in Eyes with Geographic Atrophy in GATHER | Image Credit: Duke Eye Center
Margaret Chang, MD: Two-Year Outcomes of the PDS for Diabetic Retinopathy | Image Credit: Retina Consultants Medical Group
Carl C. Awh, MD: | Image Credit:
Raj K. Maturi, MD: 4D-150 for nAMD in PRISM Population Extension Cohort | Image Credit: Retina Partners Midwest
Charles C. Wykoff, MD, PhD: Interim Analysis on Ixo-Vec Gene Therapy for nAMD | Image Credit: Retina Consultants of Texas
Sunir J. Garg, MD: Pegcetacoplan Preserves Visual Function on Microperimetry | Image Credit: Wills Eye Hospital
Edward H. Wood, MD: Pharmacodynamics of Subretinal RGX-314 for Wet AMD | Image Credit: Austin Retina Associates
Dilsher Dhoot, MD: OTX-TKI for NPDR in Interim Phase 1 HELIOS Results  | Image Credit: LinkedIn
Katherine Talcott, MD: Baseline EZ Integrity Features Predict GA Progression | Image Credit: LinkedIn
© 2024 MJH Life Sciences

All rights reserved.